Member Info for The.Italian

excellent news!very pleased.

meant to add that the 6 month term for the shareholder loan could indicate an expectation of something positive happening within that period.or it may not.and anyway the loan can no doubt be extended by agreement.

just some initial thoughts on the interims.first as expected we continue to run on fumes.no revenue to speak of.very little cash at end of june,but supplemented by DVP share sale and by shareholder loan agreement on 18th august for $2.52m repayable after 6 months. against that the convertible loans were repaid in cash on the 23rd august (reason for further DVP sale?),so guessing a couple of million or so in the kitty. under the cash flow projection it refers specifically to the possibility(presumably a certainty if nothing else materialises)of some form of fundraise.can anything else materialise?well i suppose we might get lucky and get some form of upfront payment from a japanese and/or UAE licensing partner,but absolutely no certainty that anything will be forthcoming in this regard.

if commercial supply of fortacin can be achieved and maintained we may get some form of income over time from the existing licenses,but unless fortacin is an immediate runaway success `OTC (and history hardly instils confidence in that prospect) we are presumably only looking at a very modest income over a period of time. the narrative about DLI is actually quite interesting and in different circumstances might be cause for some optimism.if we were already getting a healthy income from fortacin/senstend we might be happy to see the almost grandiose ambitions outlined in the narrative play out over a period of years,bur regrettably we do not have the luxury of time.so barring someone deciding to buy DLI off us for a premium (not expecting this of course) dli is not going to be our imminent salvation.
so whats left? i do note that the wording re the p111 trial has now changed from that used in recent reports to say that the start of the p111 trial should allow the company to advance negotiations to a final outcome in respect of out licensing the us rights to fortacin.this is a far more definite and positive wording than before,but it may be reading too much into it to attribute anything of real substance.perhaps its no more than saying the same as before but in a different way.who knows.remember the slightly enigmatic reference in the full years accounts and the cash flow projection to a $17m milestone payment in 2022 from a strategic US partner .not repeated now. do they actually have something on the anvil, just waiting for the fda blacksmith to give it the go ahead so that the shoe can be struck (sorry I've got carried away with the metaphors here!) who knows, will any of this matter to the market tomorrow? i doubt it. expecting another day of no volume and up or down a couple of percent.

just my thoughts and very happy to her anyone else's

i see at the end it refers to the terms as having been revised today,so i expect all will become clear(or not lol)

strange indeed bignose,but they have entitled it correctly,so perhaps it relates to what is to follow.big bonuses all round would be my guess!

just on the patent point,it is worth,imo,looking again at the ceo's review of the patent position in the 2021 full year report.if successful we can expect to have patent protection until 2040.one thing i always felt fairly confident about with fum was that they would get the patent position sorted.they have considerable experience of patent applications and will no doubt (bearing in mind the importance of this aspect) have ensured that they have engaged the best patent agents and attorneys to maximise the chances of a successful outcome.just my opinion of course.

apologies.wrong board!

just on the patents point, it is worth,imo, having a look again at the ceo's statement re the patent position in the 2021 full year results . if applications are successful we should have protection until 2040.one thing i always felt confident about with fum was that they would get the patent situation sorted. they have very considerable experience in the patent field and will no doubt(bearing in mind the importance of this aspect) have ensured that they have engaged the best patent agents and attorneys to maximise the chances of a successful outcome. just my opinion of course.

https://longevity.technology/insilico-medicine-boosts-latest-funding-round-to-95-million-with-aramco-backing/ interesting that insilco medicine doesn't seem to have any problem raising funds. ipo on the horizon perhaps?

please don't.i couldn't bear to read the distorted explanation we might get, crowbarred to fit his narrative.

interestingly ricketts in the recent podcast referred obliquely (well actually not that obliquely) to lanstead being out as one of the factors behind the recent s/p increase.

indeed they do.doubt they will get to $3.85 aud for remainder to get to a gain situation,but i suppose it means no additional tax liability.

in furtherance of their money tree aspirations(lol) i see we have sold another tranche.looks like they are anxious to generate cash rather than wait for s/p improvement.perhaps envisaging fda expense,although the amounts now being received are not that great.who knows.probably not long before we are out entirely now and i can stop looking at dip's s/p/

morning bignose.very interesting post. yes fum has been picking up over last few days,no doubt in expectation of positive FDA trial headline results at beginning of sept (and also i expect some momentum investing. )i now have only a very modest holding in fum, as i was fortunate (for once!)to be able to take fairly significant profits on the big spike and also a bit through trading ,since, for me, fum is at a very binary moment (not completley binary ,as it does of course already have ce mark authorisation and 4 licensing deals) in that if it gets fda approval it should do very well,but it if doesn't not so good. i imagine even with the deals already in place, if it fails the fda trial,which is essentially to see if the efficacy is maintained over 6 months as opposed to the 3 months for the eu trial ,then that will,imo,have a very negative effect and make marketing in eu etc very difficult(hard to advertise its benefits if it fails a trial). i had a very(very!)bad experience in mtfb which was completely binary and failed its p111 and i don't want to repeat that.

the disparity between fum and erp's values is interesting.erp is suffering imo because despite having approval in eu and now OTC, it hasn't been able to sell very much because of the supply difficulties and investors simply don't know if it is going gain market traction and may be waiting to see actual sales data.in a sense fum is in the same position as nothing has been actually put on the market as yet,so no data there either. both are now otc in europe, so if fum does get fda approval and is actually sold in europe it may give a good indication of how fortacin may fare once it can be supplied etc in eu etc.

you make a very pertinent point about funs core investor,lombard,which clearly has faith in the product.if erp gets fda approval eventually i would like to think IIs would be interested,but i wonder how much appetite they would have for a mellon company.the bod in fum have very few shares which may make it more appealing to IIs' although not sure why. i hope they do and completely agree that the real key here is FDA approval.i am much more confident of fortacin getting fda approval eventually than i am of FUM getting it, as we have never really had any negative trial data for fortacin,whereas i can see it is perfectly possible for med 3000 not to demonstrate the same effects over an extended period, so im not 100% confident fum will get it, hence the reduced position.

i also think that china is going be very significant for ERP,but like fda it is some way off.hoping for some news on progress re fda in interims.

sorry if this is a bit rambling.

boo now have 7.12% of revb.

yep.looks like a very good choice.

oh for the days of the hard copy manual albert.gla

oh for the days of the hard copy manual albert.gla

just thinking ahead and i found this.if you look at the end of it it refers to Q1 2023 with music and 3d nfts (whatever they are). please note i am not endorsing or recommended this in any way, as i have zero understanding of crypto and Nfts.just wondering if it may be something that would facilitate the receipt of the napster tokens https://perawallet.app/

yes, but it would be worth it!